{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:42:12Z","timestamp":1788831732960,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.gastrohep.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:06:37Z","timestamp":1655435197000},"page":"382-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0082-2189","authenticated-orcid":false,"given":"Luis","family":"Guti\u00e9rrez-Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Jos\u00e9","family":"de la G\u00e1ndara Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Garc\u00eda Buey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Uriz Otano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2022.06.001_bib0755","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0760","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"Gonz\u00e1lez-Grande","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0765","unstructured":"World Health Organization. Hepatitis C 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c [accessed 20.4.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0770","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. World Health Organization; 2019."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0775","first-page":"862","article-title":"Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)","volume":"111","author":"Crespo","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0780","unstructured":"Secretar\u00eda General de Sanidad M de S. Plan Estrat\u00e9gico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (PEAHC) 2020. https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/Plan_Estrategico_Abordaje_Hepatitis_C_(PEAHC).pdf [accessed 31.5.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0785","unstructured":"Grupo de trabajo del estudio de prevalencia de la infecci\u00f3n por hepatitis C en poblaci\u00f3n general en Espa\u00f1a; 2017-2018. Resultados del 2o Estudio de Seroprevalencia en Espa\u00f1a (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019 n.d. https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/docs\/INFORME_INFECCION_VHC_ESPANA2019.pdf [accessed 31.5.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0790","first-page":"1429","article-title":"Management of hepatitis C: evaluating suitability for drug therapy","volume":"69","author":"Ward","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0795","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1176\/ps.2006.57.4.570","article-title":"Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness","volume":"57","author":"Rifai","year":"2006","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0800","unstructured":"World Health Organization. Global Hepatitis Report, 2017 n.d. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf?sequence=1 [accessed 20.4.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0805","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.japh.2020.08.028","article-title":"HCV eradication in veterans with underlying mental health disorders and substance use","volume":"60","author":"Ifeachor","year":"2020","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0810","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.genhosppsych.2019.10.007","article-title":"Rates of hepatitis B and C in patients with schizophrenia: a meta-analysis","volume":"61","author":"Lluch","year":"2019","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0815","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1176\/appi.ps.201700542","article-title":"\u201cWhy me?.\u201d Understanding the HCV care continuum among people with serious mental illness","volume":"69","author":"Arnold","year":"2018","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0820","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.psychres.2017.08.036","article-title":"Increased risk of concurrent hepatitis C among male patients with schizophrenia","volume":"258","author":"Chiu","year":"2017","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0825","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis","volume":"3","author":"Hughes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0830","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.genhosppsych.2011.03.006","article-title":"Prevalence of liver disease in veterans with bipolar disorder or schizophrenia","volume":"33","author":"Fuller","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0835","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1176\/appi.psy.50.1.30","article-title":"Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis","volume":"50","author":"Himelhoch","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0840","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1176\/appi.psy.48.5.405","article-title":"Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort","volume":"48","author":"Freudenreich","year":"2007","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0845","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2105\/AJPH.91.1.31","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness","volume":"91","author":"Rosenberg","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0850","first-page":"19","article-title":"Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders","author":"Rosenberg","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0855","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MEG.0000000000000855","article-title":"Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment","volume":"29","author":"Roncero","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0860","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.genhosppsych.2012.11.005","article-title":"Hepatitis C among patients with mental illness in Brazil: an analysis of associated factors","volume":"35","author":"Carmo","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0865","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0272-7358(97)00019-6","article-title":"Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses","volume":"17","author":"Carey","year":"1997","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0870","doi-asserted-by":"crossref","first-page":"e0179312","DOI":"10.1371\/journal.pone.0179312","article-title":"Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder","volume":"12","author":"Lin","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0875","first-page":"57","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0880","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/00952990701522724","article-title":"Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty","volume":"33","author":"Lane","year":"2007","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0885","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.genhosppsych.2013.12.006","article-title":"Impulsiveness in chronic hepatitis C patients","volume":"36","author":"F\u00e1bregas","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0890","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/gast.2002.34750","article-title":"Psychiatric disorders among veterans with hepatitis C infection","volume":"123","author":"ElSerag","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0895","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1055\/s-0042-106731","article-title":"Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany","volume":"54","author":"H\u00fcppe","year":"2016","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0900","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10880-011-9227-6","article-title":"The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion","volume":"18","author":"Hong","year":"2011","journal-title":"J Clin Psychol Med Settings"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0905","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.psychres.2015.11.016","article-title":"Personality disorders among Spanish prisoners starting hepatitis C treatment: prevalence and associated factors","volume":"230","author":"Marco","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0910","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/09540121.2017.1313384","article-title":"HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study","volume":"29","author":"Roncero","year":"2017","journal-title":"AIDS Care"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0915","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.psychres.2016.06.024","article-title":"Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study","volume":"243","author":"Roncero","year":"2016","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0920","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.psym.2013.02.009","article-title":"Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection","volume":"54","author":"Tavakkoli","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0925","first-page":"632","article-title":"Severity of depression in hepatitis B and hepatitis C patients","volume":"22","author":"Qureshi","year":"2012","journal-title":"J Coll Physicians Surg Pakistan"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0930","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1478-3231.2010.02235.x","article-title":"Comorbidities associated with the increasing burden of hepatitis C infection","volume":"30","author":"Basseri","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0935","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200666020-00003","article-title":"Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management","volume":"66","author":"Loftis","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0940","first-page":"21","article-title":"Comorbilidade entre hepatite C e depress\u00e3o: aspectos epidemiol\u00f3gicos e etiopatog\u00e9nicos","volume":"19","author":"Neves","year":"2006","journal-title":"Acta Med Port"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0945","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpainsymman.2005.08.016","article-title":"Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection","volume":"31","author":"Lang","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0950","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.27422","article-title":"Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS)","volume":"61","author":"Boscarino","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0955","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0960","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1590\/0037-8682-0270-2013","article-title":"Depressive symptoms and harmful alcohol use in hepatitis C patients: prevalence and correlates","volume":"47","author":"Machado","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0965","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/jgh.12515","article-title":"Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C","volume":"29","author":"Wu","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0970","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.psym.2012.09.005","article-title":"Association of chronic liver disease with depression: a population-based study","volume":"54","author":"Lee","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2016.09.004","article-title":"Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon era","volume":"58","author":"Chasser","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0980","first-page":"346","article-title":"Psychiatric aspects of hepatitis C treatment","volume":"52","author":"Vrbanac","year":"2013","journal-title":"Acta Clin Croat"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0985","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21101\/cejph.a3482","article-title":"Addressing HCV infection in Europe: reported, estimated and undiagnosed cases","volume":"16","author":"Merkinaite","year":"2008","journal-title":"Cent Eur J Public Health"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0990","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15892.1","article-title":"Hepatitis C elimination: challenges with under-diagnosis and under-treatment","volume":"8","author":"Terrault","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib0995","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2105\/AJPH.2016.303059","article-title":"Hepatitis C screening rate among underserved adults with serious mental illness receiving care in California community mental health centers","volume":"106","author":"Trager","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1000","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1665-2681(19)31618-7","article-title":"Fatigue and depressive symptoms associated with chronic viral hepatitis patients\u2019 health-related quality of life (HRQOL)","volume":"9","author":"Karaivazoglou","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1005","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(99)80368-7","article-title":"Hepatitis C: the clinical spectrum of the disease","volume":"31","author":"Marcellin","year":"1999","journal-title":"J Hepatol Suppl"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1020","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1590\/s1678-9946201759081","article-title":"Quality of life in Brazilian patients with treated or untreated chronic hepatitis C","volume":"59","author":"Perlin","year":"2017","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1025","first-page":"13","article-title":"Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review","author":"Modabbernia","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/SGA.0000000000000339","article-title":"Psychological disorders and quality of life among patients with chronic viral hepatitis: a single-center cross-sectional study with pair-matched healthy controls","volume":"41","author":"Fotos","year":"2018","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jare.2016.09.005","article-title":"Hepatitis C virus infection, and neurological and psychiatric disorders \u2013 a review","volume":"8","author":"Yarlott","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1040","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.510300504","article-title":"The impact of diagnosis of hepatitis C virus on quality of life","volume":"30","author":"Rodger","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-3999(00)00155-0","article-title":"Depression, fatigue, and functional disability in patients with chronic hepatitis C","volume":"49","author":"Dwight","year":"2000","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0168-8278(01)00280-X","article-title":"Emotional distress in chronic hepatitis C patients not receiving antiviral therapy","volume":"36","author":"Fontana","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1590\/1516-4446-2014-1446","article-title":"Depression rather than liver impairment reduces quality of life in patients with hepatitis C","volume":"37","author":"Silva","year":"2015","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1399-0012.1997.tb00842.x","article-title":"Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus","volume":"11","author":"Singh","year":"1997","journal-title":"Clin Transplant"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rpsm.2018.06.003","article-title":"Efecto de los s\u00edntomas psiqui\u00e1tricos y calidad de vida sobre el desempe\u00f1o cognitivo en el VHC","volume":"13","author":"Garc\u00eda-Guerrero","year":"2020","journal-title":"Rev Psiquiatr y Salud Ment (Engl Ed)"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyg.2018.02666","article-title":"Psychosocial and neurocognitive factors associated with hepatitis C \u2013 implications for future health and wellbeing","volume":"9","author":"Barreira","year":"2019","journal-title":"Front Psychol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.20635","article-title":"Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors","volume":"41","author":"McAndrews","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1085","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1212\/01.WNL.0000158328.26897.0D","article-title":"Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine","volume":"64","author":"Cherner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-8278(03)00189-2","article-title":"Quality of life and cognitive function in hepatitis C at different stages of liver disease","volume":"39","author":"C\u00f3rdoba","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12072-018-9879-5","article-title":"Depression, fatigue and neurocognitive deficits in chronic hepatitis C","volume":"12","author":"Yeoh","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1017\/S1355617703960048","article-title":"Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C","volume":"9","author":"Hilsabeck","year":"2003","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/jhep.2002.31257","article-title":"Neuropsychological impairment in patients with chronic hepatitis C","volume":"35","author":"Hilsabeck","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/13651501.2015.1064964","article-title":"Cognitive impairment in relation to depression, anxiety and virological response in hepatitis C patients in Egypt","volume":"19","author":"Bassiony","year":"2015","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1115","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jhep.2004.07.022","article-title":"Hepatitis C virus infection affects the brain \u2013 evidence from psychometric studies and magnetic resonance spectroscopy","volume":"41","author":"Weissenborn","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2002.30688","article-title":"Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease","volume":"35","author":"Forton","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3851\/IMP3245","article-title":"Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations","volume":"23","author":"Forton","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/QAI.0b013e318240566b","article-title":"Effects of hepatitis C and HIV on cognition in women: data from the women's interagency HIV study","volume":"59","author":"Crystal","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1135","first-page":"1217","article-title":"Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C","volume":"28","author":"Ma\u0142yszczak","year":"2019","journal-title":"Adv Clin Exp Med Off Organ Wroclaw Med Univ"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1140","first-page":"1531","article-title":"The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C","volume":"28","author":"Vieira","year":"2019","journal-title":"Qual Life Res an Int J Qual Life Asp Treat Care Rehabil"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1145","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2011.02.023.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1150","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4254\/wjh.v8.i31.1318","article-title":"Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment","volume":"8","author":"Tang","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.comppsych.2015.04.010","article-title":"The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment","volume":"60","author":"Cozzolongo","year":"2015","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1165","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.mcg.0000123203.36471.70","article-title":"Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C","volume":"38","author":"Rowan","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1170","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/j.1572-0241.2005.41860.x","article-title":"Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection","volume":"100","author":"Bini","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.psym.2017.07.003","article-title":"The effect of psychosocial factors on success rates of hepatitis C treatment","volume":"58","author":"Janda","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1180","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/MEG.0b013e3283624a28","article-title":"A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use","volume":"25","author":"Sockalingam","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-4922-2","article-title":"Efficacy and tolerability of DAAs in HCV-monoinfected and HCV\/HIV-coinfected patients with psychiatric disorders","volume":"20","author":"De Gennaro","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1190","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1665-2681(19)31000-2","article-title":"Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review","volume":"12","author":"Lieveld","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2009.04004.x","article-title":"Review article: adherence to medication for chronic hepatitis C \u2013 building on the model of human immunodeficiency virus antiretroviral adherence research","volume":"30","author":"Weiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4088\/JCP.09m05282blu","article-title":"Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"72","author":"Diez-Quevedo","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.17219\/acem\/37787","article-title":"The neuropsychiatric aspect of the HCV infection","volume":"26","author":"Wi\u0229d\u0142ocha","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1210","doi-asserted-by":"crossref","first-page":"e107592","DOI":"10.1371\/journal.pone.0107592","article-title":"Predictive factors for sustained virological response after treatment with pegylated interferon \u03b1-2a and ribavirin in patients infected with HCV genotypes 2 and 3","volume":"9","author":"Niederau","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","article-title":"Systematic review: patient-reported outcomes in chronic hepatitis C \u2013 the impact of liver disease and new treatment regimens","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2334-14-203","article-title":"Factors influencing adherence in hepatitis-C infected patients: a systematic review","volume":"14","author":"Mathes","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1225","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1176\/appi.ajp.2015.14081041","article-title":"Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals","volume":"172","author":"Sockalingam","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1230","doi-asserted-by":"crossref","first-page":"e0178398","DOI":"10.1371\/journal.pone.0178398","article-title":"Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response","volume":"12","author":"Elsherif","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0033-3182(09)70843-6","article-title":"Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder","volume":"50","author":"Hauser","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000102584","article-title":"Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?","volume":"53","author":"Sch\u00e4fer","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-\u03b1-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1250","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1260","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1265","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.3748\/wjg.v25.i48.6928","article-title":"Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms","volume":"25","author":"Nardelli","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1270","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1176\/appi.psy.50.2.114","article-title":"Psychosocial issues and mental health treatment recommendations for patients with hepatitis C","volume":"50","author":"Silberbogen","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1275","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000325222","article-title":"Hepatitis C virus adversely affects quality of life","volume":"32","author":"Cillo","year":"2011","journal-title":"Blood Purif"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/NUR.0000000000000170","article-title":"Social support and adherence for military veterans with hepatitis C","volume":"30","author":"Phillips","year":"2016","journal-title":"Clin Nurse Spec"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1285","first-page":"9","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","author":"Yehia","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1290","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C: patient, provider, and system factors","volume":"20","author":"Morrill","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.psychres.2017.03.049","article-title":"Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C","volume":"253","author":"Fialho","year":"2017","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1300","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.psym.2013.06.015","article-title":"Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis","volume":"55","author":"Sarkar","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1305","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/01.psy.0000145824.82125.a8","article-title":"Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C","volume":"66","author":"H\u00e4user","year":"2004","journal-title":"Psychosom Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1310","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.pra.0000358313.06858.ea","article-title":"Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review","volume":"15","author":"Quelhas","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/NDT.S13917","article-title":"Risk factors for the development of depression in patients with hepatitis C taking interferon-\u03b1","volume":"7","author":"Smith","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1320","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0163-8343(01)00135-9","article-title":"Interferon-alpha-induced mood disorder with manic features [3]","volume":"23","author":"Altindag","year":"2001","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1325","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/MCG.0b013e3181dc24f8","article-title":"Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection","volume":"44","author":"Lim","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.genhosppsych.2004.01.003","article-title":"Suicidal ideation during interferon-\u03b12b and ribavirin treatment of patients with chronic hepatitis C","volume":"26","author":"Dieperink","year":"2004","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1335","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1023\/A:1011973823032","article-title":"Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition","volume":"46","author":"Kraus","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1340","first-page":"157","article-title":"Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population","volume":"96","author":"Ho","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1345","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence","volume":"160","author":"DiMatteo","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2893.2005.00547.x","article-title":"Reasons for non-treatment of hepatitis C in veterans in care","volume":"12","author":"Butt","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1355","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1370\/afm.62","article-title":"Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat","volume":"2","author":"Rocca","year":"2004","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1360","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.21927","article-title":"Predictors of treatment in patients with chronic hepatitis C infection \u2013 role of patient versus nonpatent factors","volume":"46","author":"Kanwal","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/ajg.2010.430","article-title":"Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study","volume":"106","author":"Kramer","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1370","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1375","first-page":"61","article-title":"New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives","author":"Welsch","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1380","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.gastrohep.2018.07.010","article-title":"Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH)","volume":"41","author":"Calleja","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1385","unstructured":"EMA. Product information Epclusa\u00ae n.d. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epclusa-epar-product-information_en.pdf [accessed 20.4.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1390","unstructured":"EMA. Product information Maviret\u00ae n.d. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf [accessed 20.4.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1395","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13110","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: an integrated analysis","volume":"26","author":"Back","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1400","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1405","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.13293","article-title":"Hepatitis C: efficacy and safety in real life","volume":"37","author":"Flisiak","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1735-6","article-title":"Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study","volume":"18","author":"Sundberg","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1420","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of direct-acting antiviral treatment with mortality among Medicare beneficiaries with hepatitis C","volume":"3","author":"Kalidindi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1425","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1590\/1516-4446-2018-0336","article-title":"Incidence of depression in patients with hepatitis C treated with direct-acting antivirals","volume":"42","author":"Egmond","year":"2020","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1430","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17512433.2018.1519392","article-title":"The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis C and psychotropic drugs","volume":"11","author":"Roncero","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1435","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1440","unstructured":"University of Liverpool. HEP Drug Interactions n.d. https:\/\/www.hep-druginteractions.org\/ [accessed 31.5.21]."},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1445","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl. 5","key":"10.1016\/j.gastrohep.2022.06.001_bib1450","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction \u2013 the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1455","first-page":"445","article-title":"Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents","volume":"111","author":"Go\u00f1i-Esarte","year":"2019","journal-title":"Rev Esp Enfermedades Dig"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1460","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/cid\/ciw496","article-title":"Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials","volume":"63","author":"Younossi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1465","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1470","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.14423","article-title":"Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-na\u00efve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3","volume":"47","author":"Younossi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1475","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1480","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1485","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","article-title":"Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1490","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.06.001_bib1495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci10080483","article-title":"Effects of direct-acting antiviral agents on the mental health of patients with chronic hepatitis C: a prospective observational study","volume":"10","author":"Fabrazzo","year":"2020","journal-title":"Brain Sci"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:46:55Z","timestamp":1759322815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570522001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0210570522001649"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.06.001","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}